Brief: Iteos And GSK Initiate Phase 3 Study Assessing Belrestotug And Dostarlimab In Non-Small Cell Lung Cancer
17/06/2024 14:18
June 17 (Reuters) - GSK plc GSK.L :
* ITEOS AND GSK INITIATE GALAXIES LUNG-301 PHASE 3 STUDY,
ASSESSING BELRESTOTUG AND DOSTARLIMAB IN PREVIOUSLY UNTREATED,
UNRESECTABLE LOCALLY ADVANCED / METASTATIC PD-L1 SELECTED
NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNXPvKK5
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on iTeos Therapeutics
See all newsIteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive